Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Baudax Bio Inc BXRXQ

Healthcare Biotechnology
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in... see more

Recent & Breaking News (GREY:BXRXQ)

Baudax Bio Announces Pricing of $5 Million Public Offering

GlobeNewswire December 2, 2022

Baudax Bio Announces 1-for-40 Reverse Stock Split

GlobeNewswire November 30, 2022

Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights

GlobeNewswire November 8, 2022

Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock

GlobeNewswire September 19, 2022

Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference

GlobeNewswire September 8, 2022

Baudax Bio Announces Closing of $6.2 Million Public Offering

GlobeNewswire September 1, 2022

Baudax Bio Announces Pricing of $6.2 Million Public Offering

GlobeNewswire August 29, 2022

Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain

GlobeNewswire August 22, 2022

Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights

GlobeNewswire August 11, 2022

Baudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000

GlobeNewswire June 1, 2022

Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference

GlobeNewswire May 18, 2022

Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire May 17, 2022

Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders

GlobeNewswire May 5, 2022

Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights

GlobeNewswire May 4, 2022

Baudax Bio to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

GlobeNewswire May 2, 2022

Baudax Bio to Present at NobleCon18 Investor Conference

GlobeNewswire April 13, 2022

Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results

GlobeNewswire March 16, 2022

Baudax Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference

GlobeNewswire March 10, 2022

Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery

GlobeNewswire March 8, 2022

Baudax Bio Regains Compliance with NASDAQ Listing Requirements

GlobeNewswire March 7, 2022